SANSURE BIOTECH INC. Financials Sansure Biotech Inc.
Equities
688289
CNE1000043J1
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.14 CNY | +1.00% |
|
-3.22% | +3.02% |
| Apr. 26 | Sansure Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Feb. 29 | Sansure Biotech's 2023 Profit Drops 81% as Revenue Slumps 84% | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Capitalization 1 | 45,580 | 23,600 | 12,747 | 11,187 |
| Enterprise Value (EV) 1 | 41,443 | 18,932 | 7,111 | 6,443 |
| P/E ratio | 16.3 x | 10.5 x | 6.63 x | 31.5 x |
| Yield | 0.99% | 1.91% | 5.91% | 2.36% |
| Capitalization / Revenue | 9.57 x | 5.23 x | 1.98 x | 11.1 x |
| EV / Revenue | 8.7 x | 4.19 x | 1.1 x | 6.4 x |
| EV / EBITDA | 13.4 x | 7.36 x | 3.13 x | 82.1 x |
| EV / FCF | 23.3 x | 21.1 x | 5.5 x | -28.3 x |
| FCF Yield | 4.29% | 4.75% | 18.2% | -3.53% |
| Price to Book | 9.61 x | 3.71 x | 1.69 x | 1.55 x |
| Nbr of stocks (in thousands) | 592,000 | 592,000 | 580,726 | 572,209 |
| Reference price 2 | 76.99 | 39.86 | 21.95 | 19.55 |
| Announcement Date | 3/29/21 | 4/18/22 | 4/18/23 | 4/26/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 303.4 | 365.4 | 4,763 | 4,515 | 6,450 | 1,007 |
| EBITDA 1 | 24.04 | 54.94 | 3,096 | 2,571 | 2,269 | 78.53 |
| EBIT 1 | 3.927 | 34.3 | 3,070 | 2,526 | 2,194 | -21.08 |
| Operating Margin | 1.29% | 9.39% | 64.45% | 55.94% | 34.01% | -2.09% |
| Earnings before Tax (EBT) 1 | 10.69 | 45.46 | 3,070 | 2,616 | 2,316 | 410.5 |
| Net income 1 | 6.762 | 39.48 | 2,617 | 2,243 | 1,937 | 363.7 |
| Net margin | 2.23% | 10.8% | 54.94% | 49.68% | 30.03% | 36.12% |
| EPS | - | 0.0743 | 4.736 | 3.790 | 3.310 | 0.6200 |
| Free Cash Flow 1 | 67.28 | -94.13 | 1,780 | 898.5 | 1,293 | -227.7 |
| FCF margin | 22.17% | -25.76% | 37.36% | 19.9% | 20.05% | -22.61% |
| FCF Conversion (EBITDA) | 279.89% | - | 57.48% | 34.95% | 57.01% | - |
| FCF Conversion (Net income) | 994.96% | - | 68.01% | 40.07% | 66.78% | - |
| Dividend per Share | - | - | 0.7601 | 0.7601 | 1.298 | 0.4622 |
| Announcement Date | 8/9/20 | 8/9/20 | 3/29/21 | 4/18/22 | 4/18/23 | 4/26/24 |
1CNY in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q3 |
|---|---|
| Net sales | - |
| EBITDA | - |
| EBIT | - |
| Operating Margin | - |
| Earnings before Tax (EBT) | - |
| Net income 1 | 208 |
| Net margin | - |
| EPS 2 | 0.3500 |
| Dividend per Share | - |
| Announcement Date | 10/30/23 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 127 | 165 | 4,137 | 4,668 | 5,636 | 4,743 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 67.3 | -94.1 | 1,780 | 899 | 1,293 | -228 |
| ROE (net income / shareholders' equity) | 1.74% | 8.28% | 98.7% | 40.3% | 27.9% | 4.66% |
| ROA (Net income/ Total Assets) | 0.44% | 3.59% | 62.9% | 25.2% | 16.9% | -0.15% |
| Assets 1 | 1,540 | 1,100 | 4,158 | 8,912 | 11,486 | -243,455 |
| Book Value Per Share | - | 1.050 | 8.020 | 10.80 | 13.00 | 12.60 |
| Cash Flow per Share | - | 0.1900 | 4.380 | 4.450 | 5.550 | 7.400 |
| Capex 1 | 32.9 | 34.1 | 109 | 373 | 559 | 391 |
| Capex / Sales | 10.84% | 9.34% | 2.28% | 8.26% | 8.66% | 38.86% |
| Announcement Date | 8/9/20 | 8/9/20 | 3/29/21 | 4/18/22 | 4/18/23 | 4/26/24 |
1CNY in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +3.02% | 1.58B | |
| -4.67% | 12.33B | |
| -5.19% | 8.14B | |
| +28.50% | 5.62B | |
| -8.09% | 4.24B | |
| -55.31% | 3.06B | |
| +13.49% | 2.76B | |
| -1.34% | 2.41B | |
| +32.24% | 2.23B | |
| -3.55% | 1.87B |
- Stock Market
- Equities
- 688289 Stock
- Financials Sansure Biotech Inc.
